Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Nature Medicine 13, 770-771 (1 July 2007) | doi:10.1038/nm0707-770;
Second chance
Abstract
Three years ago, Parkinson's disease research seemed on the verge of a breakthrough. California-based Amgen was delivering a protein directly into the brains of 34 people with the disease.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
